statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report)'s share price fell 3.9% during trading on Wednesday following insider selling activity. The stock traded as low as $28.23 and last traded...

Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 3.9% Following Insider Selling

Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Benjamin T. Dake sold 3,325 shares of the company's stock in a transaction dated Monday, April 1st. The stock was sold at an...

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 3,325 Shares

Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares

Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $30.73 and last traded at $28.72, with a volume of 14079 shares...

Aerovate Therapeutics (NASDAQ:AVTE) Sets New 12-Month High at $30.73

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aerovate Therapeutics added 'Q2 Tactical Ideas List' at Wells Fargo

Last November, Aerovate Therapeutics (NASDAQ:AVTE) announced significant progress in the development of its lead candidate treatment for rare cardi...

Aerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial Growth

Jefferies Financial Group started coverage on shares of Aerovate Therapeutics (NASDAQ:AVTE  Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The...

Jefferies Financial Group Begins Coverage on Aerovate Therapeutics (NASDAQ:AVTE)

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of...

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

AVTE's Full-Year Financials Reflect Ongoing Clinical Trial Investments and Intellectual Property ExpansionRelated Stocks: AVTE...

Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023

Aerovate Therapeutics assumed with a Buy at Jefferies

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Volume	16,008.00
52-Wk High	$32.42
52-Wk Low	$9.41

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.76	--	--	N/A
Q4'23	-$0.68	-$0.74	-9.00%	MISSED
Q3'23	-$0.69	-$0.71	-2.50%	MISSED
Q2'23	-$0.70	-$0.76	-9.20%	MISSED
Q1'23	-$0.60	-$0.67	-11.68%	MISSED

AVTE Aerovate Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals